Does additional HIPEC help after CRS in peritoneal disseminated gastric cancer?
, , , oraz
09 mar 2018
O artykule
Data publikacji: 09 mar 2018
Zakres stron: 187 - 189
Otrzymano: 29 wrz 2017
Przyjęty: 29 gru 2017
DOI: https://doi.org/10.1515/cipms-2017-0035
Słowa kluczowe
© 2017 Beate Rau et al., published by De Gruyter Open
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
The incidence of synchronous or metachronous peritoneal metastases (PM) in patients with locally advanced gastric cancer is high, and associated with a poor prognosis. The recommended therapeutic option for these patients is systemic chemotherapy and leads to a median of 7-8 months. However, new approaches like cytoreductive surgery and hyperthermic intraperitoneal chemotherapy might help to improve the median survival in selected patients.
Indications, patient selection and the choice of the chemotherapeutic agent are described in this manuscript, as well as an overview of the most recent literature about this topic.